Revolution Medicines, Inc. (RVMD) Ownership
RVMD ownership summary
as of October 18, 2026- Institutions
- 102.3% of shares outstanding
- Insiders
- 1.85% of shares outstanding
- Shares outstanding
- 214.3M
- Float
- 184.6M shares available to trade
- Short interest
- 5.88% 11.9M shares short
- Days to cover
- 5.90 short interest up 23.3% vs prior month
- Institutions 102.28%
- Insiders 1.85%
RVMD top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 6.39% | 13.7M | $2.44B | +2.5M (+22.1%) | June 30, 2026 |
| 2 | Farallon Capital Management, L.L.C. | 6.32% | 13.6M | $2.41B | −54,000 (−0.4%) | June 30, 2026 |
| 3 | FMR Inc | 5.69% | 12.2M | $2.17B | +3.7M (+44.1%) | June 30, 2026 |
| 4 | Baker Bros Advisors LP | 5.34% | 11.4M | $2.04B | +1.9M (+19.8%) | June 30, 2026 |
| 5 | Jupiter Topco LLC | 5.01% | 10.7M | $1.91B | +10.7M (0.0%) | June 30, 2026 |
| 6 | Darwin Global Management, Ltd. | 4.96% | 10.6M | $1.89B | +8.4M (+380.8%) | June 30, 2026 |
| 7 | HHG PLC | 4.56% | 9.8M | $1.74B | −2.5M (−20.6%) | March 31, 2026 |
| 8 | Vanguard Capital Management, LLC | 4.24% | 9.1M | $1.62B | +726,377 (+8.7%) | June 30, 2026 |
| 9 | Vanguard Portfolio Management, LLC | 3.87% | 8.3M | $1.48B | +792,232 (+10.6%) | June 30, 2026 |
| 10 | Nextech Invest, Ltd. | 3.55% | 7.6M | $1.35B | — | June 30, 2026 |
| 11 | Paradigm Biocapital Advisors LP | 2.97% | 6.4M | $1.13B | −294,380 (−4.4%) | June 30, 2026 |
| 12 | UBS Group AG | 2.54% | 5.4M | $969.6M | +1.1M (+24.2%) | June 30, 2026 |
| 13 | State Street Corp | 2.28% | 4.9M | $871.5M | +494,389 (+11.2%) | June 30, 2026 |
| 14 | Capital World Investors | 1.87% | 4.0M | $713.3M | +4.0M (0.0%) | June 30, 2026 |
| 15 | Geode Capital Management, LLC | 1.84% | 3.9M | $701.6M | +604,534 (+18.1%) | June 30, 2026 |
| 16 | Wellington Management Company LLP | 1.79% | 3.8M | $684.0M | −2.2M (−36.2%) | June 30, 2026 |
| 17 | JPMorgan Chase & Co | 1.54% | 3.3M | $586.9M | +3.0M (+994.3%) | June 30, 2026 |
| 18 | Bvf Inc | 1.38% | 3.0M | $527.7M | +108,378 (+3.8%) | June 30, 2026 |
| 19 | Alphabet Inc | 1.37% | 2.9M | $524.4M | −345,906 (−10.5%) | June 30, 2026 |
| 20 | Casdin Capital, LLC | 1.20% | 2.6M | $458.7M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 38.1M shares and 5 cut 5.4M.
RVMD top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 3.00% | 6.4M | $1.14B | −12,663 (−0.2%) | August 31, 2026 |
| 2 | Vanguard Small Cap Index | 2.14% | 4.6M | $815.6M | −63,910 (−1.4%) | September 30, 2026 |
| 3 | American Funds Growth Fd of Amer A | 1.38% | 3.0M | $527.6M | — | September 30, 2026 |
| 4 | Vanguard MStar Small Cap Growth Indx Inv | 1.19% | 2.6M | $453.8M | −116,866 (−4.4%) | September 30, 2026 |
| 5 | Fidelity Growth Company Fund | 1.15% | 2.5M | $440.1M | — | August 31, 2026 |
| 6 | JPMorgan Large Cap Growth I | 1.00% | 2.1M | $380.9M | — | August 31, 2026 |
| 7 | Vanguard Health Care Inv | 0.98% | 2.1M | $372.7M | −481,104 (−18.7%) | June 30, 2026 |
| 8 | MFS Mid Cap Growth A | 0.73% | 1.6M | $277.3M | +97,176 (+6.7%) | August 31, 2026 |
| 9 | iShares Biotechnology ETF | 0.70% | 1.5M | $267.7M | −11,392 (−0.8%) | September 30, 2026 |
| 10 | iShares Russell Mid-Cap Growth ETF | 0.50% | 1.1M | $191.5M | −1,149 (−0.1%) | September 30, 2026 |
| 11 | Fidelity OTC | 0.47% | 1.0M | $178.5M | — | August 31, 2026 |
| 12 | Franklin DynaTech Fund A | 0.47% | 1.0M | $178.0M | +100,000 (+11.1%) | August 31, 2026 |
| 13 | Janus Henderson Enterprise D | 0.46% | 978K | $174.1M | — | August 31, 2026 |
| 14 | Fidelity Extended Market Index | 0.45% | 973K | $173.1M | −9,791 (−1.0%) | August 31, 2026 |
| 15 | Janus Henderson Forty S | 0.44% | 938K | $166.9M | — | August 31, 2026 |
| 16 | Janus Global Life Science AUSD | 0.40% | 861K | $153.1M | −132,165 (−13.3%) | June 30, 2026 |
| 17 | iShares Russell Mid-Cap ETF | 0.37% | 790K | $140.7M | +1,463 (+0.2%) | September 30, 2026 |
| 18 | Fidelity Select Biotechnology | 0.34% | 735K | $130.8M | +20,200 (+2.8%) | August 31, 2026 |
| 19 | Fidelity Mid Cap Index | 0.34% | 728K | $129.5M | +2,827 (+0.4%) | August 31, 2026 |
| 20 | iShares Russell 1000 Growth ETF | 0.33% | 718K | $127.8M | −490 (−0.1%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
RVMD insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | Mark A Goldsmith | Sell | $150.09 | 120,000 | $18.0M |
| 2026-03-17 | Jack Anders | Sell | $99.48 | 2,753 | $273,868 |
| 2026-03-17 | Lin Wei | Sell | $99.48 | 2,073 | $206,222 |
| 2026-03-17 | Margaret A Horn | Sell | $99.48 | 4,583 | $455,917 |
| 2026-03-17 | Mark A Goldsmith | Sell | $99.48 | 12,871 | $1.3M |
| 2026-03-17 | Stephen Michael Kelsey | Sell | $99.48 | 4,302 | $427,963 |
| 2026-03-17 | Xiaolin Wang | Sell | $99.48 | 2,010 | $199,955 |
| 2026-03-02 | Mark A Goldsmith | Sell | $101.22 | 30,000 | $3.0M |
| 2026-03-02 | Mark A Goldsmith | Sell | $101.30 | 6,000 | $607,800 |
| 2026-01-07 | Jack Anders | Sell | $98.00 | 10,000 | $980,000 |
| 2026-01-07 | Margaret A Horn | Sell | $100.56 | 75,000 | $7.5M |
| 2025-12-16 | Stephen Michael Kelsey | Sell | $76.82 | 5,447 | $418,439 |
| 2025-12-16 | Mark A Goldsmith | Sell | $76.82 | 15,394 | $1.2M |
| 2025-12-16 | Margaret A Horn | Sell | $76.82 | 4,847 | $372,347 |
| 2025-12-16 | Jack Anders | Sell | $77.09 | 3,104 | $239,287 |
| 2025-11-25 | Mark A Goldsmith | Sell | $75.08 | 60,000 | $4.5M |
| 2025-11-18 | Mark A Goldsmith | Sell | $70.38 | 20,000 | $1.4M |
| 2025-11-12 | Mark A Goldsmith | Sell | $65.07 | 20,000 | $1.3M |
| 2025-11-07 | Mark A Goldsmith | Sell | $60.31 | 30,000 | $1.8M |
| 2025-10-13 | Stephen Michael Kelsey | Sell | $48.54 | 25,000 | $1.2M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
RVMD shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns RVMD
Institutional investors own 102.3% of Revolution Medicines's shares and insiders 1.85%. The largest holder is BlackRock Inc with 6.39% of the shares (13.7M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 5 reduced their stake in the latest filings. Short interest is 5.88% of the float, or 5.90 days of average trading volume. The share count rose 9,406.5% since 2017.
Related: RVMD analyst forecast, RVMD key metrics. See the RVMD stock overview for the latest quote and news.
RVMD ownership FAQ
Who owns the most Revolution Medicines stock?
The largest shareholders of Revolution Medicines are BlackRock Inc (6.39%), Farallon Capital Management, L.L.C. (6.32%), FMR Inc (5.69%), Baker Bros Advisors LP (5.34%), Jupiter Topco LLC (5.01%).
What percentage of Revolution Medicines is owned by institutions?
Institutions hold 102.3% of Revolution Medicines's shares outstanding; insiders hold 1.85%.
Which funds own Revolution Medicines?
The largest fund holders of Revolution Medicines are Vanguard MStar Total Stk Mkt Idx Invest (3.00%), Vanguard Small Cap Index (2.14%), American Funds Growth Fd of Amer A (1.38%), Vanguard MStar Small Cap Growth Indx Inv (1.19%), Fidelity Growth Company Fund (1.15%).
What is Revolution Medicines's short interest?
11.9M shares of Revolution Medicines were sold short, 5.88% of the float; at the average daily volume it would take 5.90 days to cover.
Are insiders buying or selling Revolution Medicines?
Of the latest 20 reported insider transactions in Revolution Medicines (since October 13, 2025), 0 were purchases and 20 were sales.
How many shares of Revolution Medicines are outstanding?
Revolution Medicines has 214.3M shares outstanding, of which 184.6M are in the public float.